secwatch / observer
8-K filed August 9, 2022, 7:59 PM ET ticker SGMO CIK 0001001233
leadership confidence high sentiment neutral materiality 0.40

Sangamo Therapeutics loses Head of Development; internal replacement named

SANGAMO THERAPEUTICS, INC

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rob Schott

Senior Vice President, Head of Development
SGMO · SANGAMO THERAPEUTICS, INC
Effective
2022-08-19
Successor
Nathalie Dubois-Stringfellow
Filed
August 9, 2022, 7:59 PM ET
On August 8, 2022, Rob Schott, M.D., M.P.H., F.A.C.C., Senior Vice President, Head of Development of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his resignation from this position and from his employment with the Company, with such resignation to be effective on August 19, 2022, in order to pursue a new opportunity.
Appointed

Nathalie Dubois-Stringfellow

Senior Vice President, Head of Development
SGMO · SANGAMO THERAPEUTICS, INC
Effective
2022-08-19
Filed
August 9, 2022, 7:59 PM ET
Effective August 19, 2022, Nathalie Dubois-Stringfellow, Ph.D., currently serving as Senior Vice President, Product Development and Management, will assume the role of Senior Vice President, Head of Development of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rob Schott resigned as Senior Vice President, Head of Development at SANGAMO THERAPEUTICS, INC.

Action
resigned
Role
Senior Vice President, Head of Development
Exact text from the filing
On August 8, 2022, Rob Schott, M.D., M.P.H., F.A.C.C., Senior Vice President, Head of Development of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his resignation from this position and from his employment with the Company, with such resignation to be effective on August 19, 2022, in order to pursue a new opportunity.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Nathalie Dubois-Stringfellow was appointed as Senior Vice President, Head of Development at SANGAMO THERAPEUTICS, INC.

Action
appointed
Role
Senior Vice President, Head of Development
Exact text from the filing
Effective August 19, 2022, Nathalie Dubois-Stringfellow, Ph.D., currently serving as Senior Vice President, Product Development and Management, will assume the role of Senior Vice President, Head of Development of the Company.
View on SEC.gov

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR
accession 0001628280-22-021955
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.